Katalin Karikó Patents & Innovation Profile — PatSnap Eureka
Katalin Karikó: Patent Portfolio & Innovation Analysis
Katalin Karikó is a Hungarian-American biochemist who holds 339 patents spanning messenger RNA nucleoside modification, mRNA purification, and lipid nanoparticle vaccine delivery, with institutional affiliations at the University of Pennsylvania and BioNTech SE across a career extending from the 1990s through 2024. Her foundational research on pseudouridine-modified mRNA — widely dismissed for years before its validation — underpins the Pfizer–BioNTech BNT162b2 COVID-19 vaccine and earned her the 2023 Nobel Prize in Physiology or Medicine jointly with Drew Weissman.
Citation Impact by Publication Year
Top cited papers span 2004–2021; the 2014 mRNA therapeutics review leads with 1,719 citations.
Katalin Karikó's Publication & Citation Patterns
Karikó's 39 indexed publications span two decades, with citation peaks in 2005 (innate immunity) and 2014 (mRNA therapeutics review), reflecting the foundational nature of her research across three distinct thematic clusters.
Citations by Publication Year
The 2014 mRNA therapeutics review (1,719 citations) and 2005 TLR suppression paper (1,712 citations) are the two most cited works in Karikó's indexed output.
Research Theme Distribution
Three thematic clusters define Karikó's 39-paper output: innate immunity & nucleoside modification, mRNA delivery & LNP formulation, and clinical-stage vaccine applications.
Core Areas of Innovation
Katalin Karikó's 339 patents and 39 publications cluster into three interconnected technology domains that collectively define the modern mRNA therapeutics platform.
Nucleoside Modification & Innate Immune Evasion
Core domainPatents and publications in this domain cover methods for incorporating naturally modified nucleosides — particularly pseudouridine — into synthetic mRNA to prevent activation of Toll-like receptors TLR3, TLR7, and TLR8, enabling therapeutic mRNA to evade innate immune detection. This cluster contains Karikó's most foundational and most litigated IP.
- Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification (2005)
- Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation (2010)
- mRNA Is an Endogenous Ligand for Toll-like Receptor 3 (2004)
mRNA Purification & Manufacturing Quality Control
Process IPThis domain covers in vitro transcription optimisation and HPLC-based removal of immunostimulatory double-stranded RNA contaminants generated during IVT reactions. The 2011 HPLC purification paper (807 citations) is a key prior art document for any competitor patenting mRNA manufacturing quality control methods.
- Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation (2011)
- IVT mRNA dsRNA contaminant removal methods
- Cap structure optimisation for translational efficiency
Lipid Nanoparticle Delivery & mRNA Formulation
Delivery platformPatents and papers in this domain address the encapsulation of nucleoside-modified mRNA in lipid nanoparticles (LNPs) for in vivo delivery, including expression kinetics by route of administration, LNP composition parameters, and the immunological outcomes of LNP-formulated mRNA vaccines in preclinical and clinical settings.
- Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles (2015)
- Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines (2021)
- Nucleoside-modified mRNA vaccines induce potent T follicular helper responses (2018)
mRNA Vaccine Platforms — Infectious Disease
Clinical translationThis domain encompasses mRNA-based vaccine development for SARS-CoV-2, influenza, Zika virus, and HIV, applying the nucleoside-modified mRNA-LNP platform to generate protective immune responses. BNT162b1 and BNT162b2 clinical data papers represent the apex of this translational work.
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (2020)
- Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination (2017)
- Influenza hemagglutinin stalk mRNA vaccine applications
Oncology & Emerging Therapeutic Applications
Emerging pipelineThe most recent literature extends the mRNA-LNP platform to oncology (paediatric brain tumour CAR-T cell therapy), rare disease (VEGFC mRNA for lymphedema), and personalised cancer vaccines, signalling where the next generation of patent filings from BioNTech and University of Pennsylvania is likely to concentrate.
- mRNA-based CAR-T cell therapy for paediatric brain tumours
- VEGFC mRNA therapy for lymphedema treatment
- Personalised cancer neoantigen mRNA vaccine platforms
Katalin Karikó's Highest-Impact Research
Karikó's top 10 indexed publications have accumulated over 8,800 combined citations, with three papers exceeding 900 citations each — an exceptional concentration of influence in a single inventor's output.
| Title | Year | Citations | Institution |
|---|---|---|---|
| mRNA-based therapeutics — developing a new class of drugs | 2014 | 1,719 ↑ | BioNTech / University of Pennsylvania |
| Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA | 2005 | 1,712 ↑ | University of Pennsylvania School of Medicine |
| COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses | 2020 | 1,475 ↑ | BioNTech / Pfizer / Regeneron |
| mRNA Is an Endogenous Ligand for Toll-like Receptor 3 | 2004 | 956 ↑ | University of Pennsylvania |
| Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA | 2011 | 807 ↑ | University of Pennsylvania |
| Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes | 2015 | 704 ↑ | University of Pennsylvania / Acuitas |
| Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines | 2021 | 633 ↑ | University of Pennsylvania / BioNTech |
| Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination | 2017 | 492 ↑ | NIH / University of Pennsylvania / BioNTech |
| Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses | 2018 | 480 ↑ | University of Pennsylvania / BioNTech / Acuitas |
| Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation | 2010 | 601 ↑ | University of Pennsylvania |
Katalin Karikó's Research Collaborators
Co-Author Citation Frequency
Collaboration Highlights
Karikó's most consequential collaboration is with immunologist Drew Weissman at the University of Pennsylvania — their 2005 Immunity paper on nucleoside modification and TLR suppression (1,712 citations) and subsequent co-authored work form the scientific and IP bedrock of the entire mRNA therapeutics field. Her transition to BioNTech added a second major collaboration cluster with Ugur Sahin, Özlem Türeci, and the clinical development team behind BNT162b2.
- Drew Weissman Co-Nobel laureate · 2023
- Ugur Sahin BioNTech CEO
- Norbert Pardi LNP delivery research
- Pieter Cullis Acuitas / LNP formulation
- Özlem Türeci BioNTech co-founder
Research Literature by Katalin Karikó
39 papers indexed · Spanning foundational innate immunity (2004) through clinical COVID-19 vaccine data (2020) to emerging oncology and rare disease applications (2024)
| Title | Year | Citations | Institution / Source |
|---|---|---|---|
| mRNA-based therapeutics — developing a new class of drugs | 2014 | 1,719 ↑ | BioNTech / TRON / University of Pennsylvania |
| Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA | 2005 | 1,712 ↑ | University of Pennsylvania School of Medicine |
| COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses | 2020 | 1,475 ↑ | BioNTech / Pfizer / Regeneron / UTMB |
| mRNA Is an Endogenous Ligand for Toll-like Receptor 3 | 2004 | 956 ↑ | University of Pennsylvania |
| Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA | 2011 | 807 ↑ | University of Pennsylvania / University of Bonn |
🧬 Innate Immunity & Nucleoside Modification
The 2004–2011 cluster defines the immune evasion problem and its solution: pseudouridine incorporation prevents TLR3/7/8 activation and PKR-mediated translational suppression. These papers are cited in virtually every subsequent mRNA therapeutics patent application globally.
💉 mRNA Delivery & LNP Formulation
The 2015–2018 delivery cluster, produced in collaboration with Acuitas Therapeutics, documents the consolidation of the LNP delivery platform that enabled BNT162b2 — covering expression kinetics, route of administration, and T follicular helper cell induction.
🌐 Clinical Vaccines & Emerging Applications
The 2020–2024 cluster documents BNT162b1/b2 clinical translation and extends the platform to HIV, Zika, influenza stalk, lymphedema (VEGFC mRNA), and paediatric brain tumour CAR-T therapy — signalling the next wave of patent filings.
Katalin Karikó's International Research & IP Reach
Karikó's institutional affiliations and co-author networks span the United States, Germany, Canada, and beyond, reflecting a global collaboration strategy that mirrors the multinational patent filing approach of her primary assignees.
Filing Markets & Institutional Geography
Karikó's career trajectory maps directly onto a transatlantic IP strategy: foundational patents filed from the United States (University of Pennsylvania, Philadelphia) cover the core nucleoside modification and purification methods, while the BioNTech phase adds a German filing anchor. The Acuitas collaboration brings Canadian co-inventorship into the LNP delivery layer, and clinical trial partnerships extend the co-author geography to the UK and beyond. With 339 total patents, the portfolio spans the major pharmaceutical jurisdictions required for global market exclusivity.
Why Katalin Karikó's Portfolio Matters
Strategic implications for patent attorneys, in-house IP teams, and R&D strategists operating in the nucleic acid therapeutics space.
FTO Considerations
Any company developing mRNA therapeutics — whether vaccines, protein replacement therapies, or CAR-T mRNA applications — must account for the multiple technology layers covered by Karikó's 339-patent portfolio: nucleoside modification, HPLC purification, LNP formulation parameters, and cap structure optimisation each carry independent coverage. The breadth of this IP means that FTO analyses cannot be conducted at the level of a single patent family — systematic landscaping across all associated assignees (University of Pennsylvania and BioNTech SE) is required.
Prior Art Relevance
Karikó's published papers date to 2004–2005 and are indexed with full text in patent databases, making them strong prior art for any competitor attempting to independently patent nucleoside modification strategies, HPLC-based dsRNA removal methods, or pseudouridine-mediated PKR inhibition. The 2011 HPLC purification paper (807 citations) predates many secondary patent filings on mRNA manufacturing quality control and would be a natural starting point for invalidation arguments. The 2005 Immunity paper (1,712 citations) is cited in virtually every subsequent mRNA therapeutics patent application globally.
Katalin Karikó — Patent & Research Questions
The database records 339 patents associated with Katalin Karikó or Katalin K. Karikó, reflecting her contributions across her academic career at the University of Pennsylvania and her industrial tenure at BioNTech RNA Pharmaceuticals. This portfolio spans nucleoside modification, mRNA purification, lipid nanoparticle delivery, and clinical vaccine applications.
Her two most cited works are a 2014 review on mRNA-based therapeutics (1,719 citations, co-authored at BioNTech/TRON) and the landmark 2005 Immunity paper on nucleoside modification and TLR suppression (1,712 citations, University of Pennsylvania). The 2020 BNT162b1 clinical data paper has accumulated 1,475 citations. All three are available via PatSnap Eureka's literature database.
Karikó's work centres on three interconnected areas: (1) the immunology of synthetic mRNA and methods to suppress innate immune activation through nucleoside modification, particularly pseudouridine incorporation to prevent TLR3, TLR7, and TLR8 activation; (2) optimisation of in vitro transcription and mRNA purification, including HPLC-based removal of immunostimulatory dsRNA contaminants; and (3) lipid nanoparticle-formulated mRNA vaccine platforms for infectious disease and oncology applications.
The University of Pennsylvania was the primary assignee of her foundational IP through approximately 2013. Following her move to Germany, BioNTech RNA Pharmaceuticals (subsequently BioNTech SE) became the dominant institutional assignee. Several key patents have joint University of Pennsylvania and BioNTech provenance, reflecting the collaborative nature of the translational work.
Karikó's foundational research on pseudouridine-modified mRNA — developed years before the pandemic — is the biological basis for both the Pfizer–BioNTech BNT162b2 and Moderna mRNA-1273 vaccines. The IP that arose from this research has been at the centre of multiple high-profile patent disputes, including Moderna's 2022 lawsuit against Pfizer and BioNTech. Understanding Karikó's publication timeline and the corresponding patent priority dates is essential for any legal or competitive analysis of COVID-19 vaccine IP.
The relationship is unusually direct. Each major publication cluster corresponds to a layer of patent activity: the 2004–2005 innate immunity papers preceded and informed the core nucleoside modification patents; the 2011 HPLC purification paper (807 citations) aligns with manufacturing process patents; and the 2015–2018 LNP delivery papers correspond to formulation and delivery IP. Her published work effectively documents the inventive sequence that the patent filings formalised, making her publication record an essential map for prior art searches in this space.
Analyse Katalin Karikó's Full Patent Portfolio in PatSnap Eureka IP
Access all 339 patents, full citation mapping, FTO screening, assignee history, and prosecution monitoring across the mRNA therapeutics landscape — the most consequential IP environment in modern biotechnology.
References & External Sources
- Karikó K. et al. (2005). Suppression of RNA Recognition by Toll-like Receptors. Immunity. Available via PatSnap Eureka.
- Karikó K. et al. (2011). Generating the optimal mRNA for therapy: HPLC purification. Available via PatSnap Eureka.
- USPTO Patent Full-Text Database. patents.google.com
- European Patent Office — Espacenet. epo.org
- WIPO PATENTSCOPE. wipo.int/patentscope
- Nobel Prize in Physiology or Medicine 2023. nobelprize.org
PatSnap Eureka searches 208M+ patents and papers to answer instantly.